RNA Disruption Assay Using Electropherogram Features for Chemotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for assessing RNA integrity in response to cytotoxic treatments like chemotherapy and radiation therapy are inadequate, as they rely on subjective comparisons and lack objective, automated measures for determining RNA disruption and treatment response.
Innovation Solution
An RNA Disruption Assay (RDA) is developed to quantify RNA disruption by analyzing electropherograms, identifying 18S and 28S peaks, and calculating an RDA score based on feature values, which can determine sensitivity to treatments and predict treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional RNA integrity assessment methods are used, then the assessment process is simple, but the measurement precision is poor due to misidentification of RNA peaks and aberrant ratios in partially degraded samples
Solution Approach 1:
The assay segments the RNA electropherogram into distinct regions (18S peak region, 28S peak region, and intermediate region) and analyzes each region separately using region-specific features. This segmentation allows accurate measurement of RNA disruption by focusing on characteristic patterns in each region rather than relying on simple overall ratios that fail in partially degraded samples.
Solution Approach 2:
The invention transitions from traditional two-dimensional analysis (simple peak ratio measurements) to a multi-dimensional feature space that includes multiple electropherogram regions and numerous features (area, height, width, skewness, kurtosis) for each region. This dimensional expansion enables more precise discrimination between intact and degraded RNA states.
2Ease of operation
If automated RNA quality control algorithms are used, then the ease of operation is improved, but the measurement precision deteriorates due to peak misidentification in treated samples
Solution Approach 1:
The assay applies different analysis strategies and feature sets to different regions of the electropherogram based on local characteristics. The 18S region, 28S region, and intermediate region each have tailored feature calculations that account for their specific patterns in treated versus untreated samples, improving peak identification accuracy while maintaining automation.
Solution Approach 2:
The invention changes the parameters used for peak identification from simple ratio-based metrics to a comprehensive set of regional features including area, height, width, skewness, and kurtosis. These parameter changes enable the automated algorithm to accurately distinguish peaks even in partially degraded samples where traditional methods fail.
3Reliability
If simple peak ratio methods are used, then the device complexity is low, but the reliability is poor in predicting treatment response
Solution Approach 1:
The assay performs preliminary analysis by calculating multiple regional features (area, height, width, skewness, kurtosis) for the 18S, 28S, and intermediate regions before making a treatment response prediction. This preliminary computation of comprehensive features ensures reliable prediction by capturing subtle patterns that simple ratios miss, while the structured approach maintains assay organization.
Solution Approach 2:
The invention combines multiple feature types (area, height, width, skewness, kurtosis) from multiple regions (18S, 28S, intermediate) into a composite analysis framework. This composite approach creates a robust prediction model that reliably distinguishes responders from non-responders by integrating information from across the entire electropherogram rather than relying on a single simple ratio.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RDA provides an objective and automated method to assess RNA disruption, enabling accurate prediction of treatment response and guiding treatment adjustments in cancer therapy.
Implementation Method 1
obtain at least one electropherogram dataset corresponding to a unique biological sample comprising cellular RNA
Data Source
AI summary
Various embodiments are described herein related to an assay, method and apparatus for performing an RNA Disruption Assay (RDA) for cellular RNA optionally in response to a cytotoxic treatment such as chemotherapy and/or radiation treatment. The method comprises obtaining at least one electropherogram dataset corresponding to a unique biological sample comprising the cellular RNA at a time point, optionally during or after the treatment; determining values for features from at least two shifted regions of the at least one electropherogram dataset, the shifting being due to the treatment; and optionally determining an RDA score based on a combination of the values of the features.